H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio's (CLYM) Budoprutug Across Clinical Tracks [Yahoo! Finance]
Climb Bio, Inc. (CLYM)
Company Research
Source: Yahoo! Finance
Wainwright analyst Raghuram Selvaraju raised the firm's price target on Climb Bio to $11 from $9, while maintaining a Buy rating on the shares. This sentiment was announced as the firm believes that Budoprutug's progress across clinical tracks will culminate in the release of data readouts during 2026. The company is currently focused on two primary assets: Budoprutug, which is an anti-CD19 antibody targeting B-cell mediated diseases, and CLYM116, which is an anti-APRIL antibody for IgA nephropathy. Leadership characterized 2026 as a data-rich year, with multiple readouts expected to guide the next phase of development for both programs. Climb Bio Inc. (NASDAQ:CLYM) initiated the PrisMN Phase 2 trial for Budoprutug in Primary Membranous Nephropathy/pMN in Q3 2025. This open-label, dose-ranging study aims to evaluate safety, pharmacokinetics, and preliminary efficacy, specifically complete and partial remission, to identify a dose for Phase 3. Additionally, a Phase 1 trial for a su
Show less
Read more
Impact Snapshot
Event Time:
CLYM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLYM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLYM alerts
High impacting Climb Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CLYM
News
- Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026GlobeNewswire
- Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Climb Bio (NASDAQ:CLYM) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
CLYM
Earnings
- 3/25/25 - Beat
CLYM
Analyst Actions
- 12/18/25 - HC Wainwright
CLYM
Sec Filings
- 1/8/26 - Form 4
- 1/8/26 - Form 4
- 1/8/26 - Form 4
- CLYM's page on the SEC website